163 related articles for article (PubMed ID: 36909350)
1. Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution: An 8-Weeks Phase III Study.
Kuna P; Jutel M; Pulka G; Tokarski S; Arranz P; Hernández G; Fernández Hernando N
Clin Ophthalmol; 2023; 17():735-746. PubMed ID: 36909350
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Once-Daily Ophthalmic Bilastine for the Treatment of Allergic Conjunctivitis: A Dose-Finding Study.
Gomes PJ; Ciolino JB; Arranz P; Hernández G; Fernández N
J Investig Allergol Clin Immunol; 2023 Jul; 33(4):271-280. PubMed ID: 35234641
[TBL] [Abstract][Full Text] [Related]
3. Bilastine 0.6% Preservative-free Eye Drops: A Once-daily Treatment for Allergic Conjunctivitis.
Gomes PJ; Ciolino JB; Arranz P; Hernández G; Fernández N
J Investig Allergol Clin Immunol; 2024 Jun; 34(3):167-176. PubMed ID: 36811846
[TBL] [Abstract][Full Text] [Related]
4. Bilastine 0.6% preservative-free eye drops, an effective once-daily treatment to reduce signs and symptoms of allergic conjunctivitis: A pooled analysis of two randomized clinical trials.
Gomes PJ; Ciolino JB; Arranz P; Gonzalo A; Fernández N; Hernández G
J Investig Allergol Clin Immunol; 2023 Sep; ():0. PubMed ID: 37732873
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study.
Okubo K; Gotoh M; Asako M; Nomura Y; Togawa M; Saito A; Honda T; Ohashi Y
Allergol Int; 2017 Jan; 66(1):97-105. PubMed ID: 27421817
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases.
Novák Z; Yáñez A; Kiss I; Kuna P; Tortajada-Girbés M; Valiente R;
Pediatr Allergy Immunol; 2016 Aug; 27(5):493-8. PubMed ID: 26918853
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis.
Sastre J; Mullol J; Valero A; Valiente R;
Curr Med Res Opin; 2012 Jan; 28(1):121-30. PubMed ID: 22077106
[TBL] [Abstract][Full Text] [Related]
8. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
Crampton HJ
Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study.
Kuna P; Bachert C; Nowacki Z; van Cauwenberge P; Agache I; Fouquert L; Roger A; Sologuren A; Valiente R;
Clin Exp Allergy; 2009 Sep; 39(9):1338-47. PubMed ID: 19438584
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of bilastine following up to 12 weeks or 52 weeks of treatment in Japanese patients with allergic rhinitis: Results of an open-label trial.
Okubo K; Gotoh M; Togawa M; Saito A; Ohashi Y
Auris Nasus Larynx; 2017 Jun; 44(3):294-301. PubMed ID: 27561709
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis.
Abelson MB; Turner D
Clin Ther; 2003 Mar; 25(3):931-47. PubMed ID: 12852709
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation.
Ochoa D; Román M; Belmonte C; Martín-Vilchez S; Mejía-Abril G; Abad-Santos F; Hernández G; Arranz P; Elgezabal L; Fernández N
Adv Ther; 2021 Jul; 38(7):4070-4081. PubMed ID: 34125400
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients.
Bachert C; Kuna P; Sanquer F; Ivan P; Dimitrov V; Gorina MM; van de Heyning P; Loureiro A;
Allergy; 2009 Jan; 64(1):158-65. PubMed ID: 19132976
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
Spangler DL; Abelson MB; Ober A; Gotnes PJ
Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study.
Hide M; Yagami A; Togawa M; Saito A; Furue M
Allergol Int; 2017 Apr; 66(2):317-325. PubMed ID: 27599913
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.
Whitcup SM; Bradford R; Lue J; Schiffman RM; Abelson MB
Clin Ther; 2004 Jan; 26(1):29-34. PubMed ID: 14996515
[TBL] [Abstract][Full Text] [Related]
18. Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects.
Malhotra RP; Meier E; Torkildsen G; Gomes PJ; Jasek MC
Clin Ophthalmol; 2019; 13():403-413. PubMed ID: 30858690
[TBL] [Abstract][Full Text] [Related]
19. Open-label safety assessment of bilastine in elderly patients with allergic rhinoconjunctivitis and/or urticaria.
Sologuren A; Viñas R; Cordón E; Riesgo SE; Del Mar Forés M; Senán MR; Fernández S; Labeaga L; Ruiz-Miján M
Allergy Asthma Proc; 2018 Jul; 39(4):299-304. PubMed ID: 29559031
[TBL] [Abstract][Full Text] [Related]
20. Effect of alcaftadine 0.25% on ocular itch associated with seasonal or perennial allergic conjunctivitis: a pooled analysis of two multicenter randomized clinical trials.
Ciolino JB; McLaurin EB; Marsico NP; Ackerman SL; Williams JM; Villanueva L; Hollander DA
Clin Ophthalmol; 2015; 9():765-72. PubMed ID: 25999684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
